Thank you to Elaine Benoit, Precision BioLogic Inc., for this heads-up. Takeda Pharmaceuticals U.S.A. Inc. announced it has discontinued the production of therapeutics HEMOFIL M® and RECOMBINATE®. HEMOFIL M, developed by Baxter Hyland, is a human plasma-derived factor concentrate approved by the US FDA in 1966 for on-demand hemophilia A therapy. RECOMBINATE, also developed by … Continue reading Hemophilia Therapeutics Discontinued